Skip to content
★ Sign in to follow
WD

Wesley Day

Executive
Vivus Inc
Total declarations
27
Company
1
▲ Purchases (5 ops.)
€44k
▼ Sales (11 ops.)
€3.1M

Latest filing published 20 Apr 2016 for VIVUS INC, €6,854.

Insider track record

Disclosed buys
5
Disclosed sells
11
Signal history

No signal scores available.

Closed purchases

Market purchases
5

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Wesley Day: trading record in brief

Wesley Day appears in our data through filings on Vivus Inc shares, published by SEC (Form 4). In total, 27 filings cover trades dated from 2 March 2006 to 1 July 2015.

The open-market side counts 5 purchases for €44k alongside 11 sales for €3.1M. The net balance comes to €3.1M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 3 share grants and 7 option exercises. So far in 2016, the count stands at no purchases and 1 sale.

In size, the median ticket on the buying side is €8,962.

The record was last updated on 20 April 2016 with an open-market sale (€6,854) in Vivus Inc. The latest purchase dates back some time: it was published 6,748 days ago, on 19 May 2008. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Wesley Day

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations27 total
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    7,749 USD0SEC
    2,549 shares@ US$3.04Common StockSEC:0001123292-16-002113:0
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    18,284 USD0SEC
    7,881 shares@ US$2.32Common StockSEC:0001123292-15-001000:0
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    1,312 USD0SEC
    472 shares@ US$2.78Common StockSEC:0001104659-15-005694:0
  • ◆
    VP, Clinical DevelopmentExecutivesVivus Inc
    0SEC
    24,500 shares0Common StockSEC:0001104659-15-004782:0
  • ●
    VP, Clinical DevelopmentExecutivesVivus Inc
    12,112 USD0SEC
    2,281 shares@ US$5.31Common StockSEC:0001104659-14-050311:0
  • ◆
    VP, Clinical DevelopmentExecutivesVivus Inc
    0SEC
    4,200 shares0Common StockSEC:0001104659-14-005314:0
  • ◆
    VP, Clinical DevelopmentExecutivesVivus Inc
    0SEC
    30,000 shares0Common StockSEC:0001104659-14-004123:0
  • ▼
    VP, Clinical ResearchExecutivesVivus Inc
    510,048 USD0SEC
    16,800 shares@ US$30.36Common StockSEC:0001104659-12-050215:0
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    32,662 USD0SEC
    9,958 shares@ US$3.28Common StockSEC:0001104659-12-012638:0
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    206,031 USD0SEC
    9,958 shares@ US$20.69Common StockSEC:0001104659-12-012638:1
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    83,887 USD0SEC
    19,738 shares@ US$4.25Common StockSEC:0001104659-12-012638:2
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    408,379 USD0SEC
    19,738 shares@ US$20.69Common StockSEC:0001104659-12-012638:3
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    213,614 USD0SEC
    50,262 shares@ US$4.25Common StockSEC:0001104659-12-012638:4
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    1M USD0SEC
    50,262 shares@ US$20.69Common StockSEC:0001104659-12-012638:5
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    98,400 USD0SEC
    30,000 shares@ US$3.28Common StockSEC:0001104659-12-001583:0
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    345,000 USD0SEC
    30,000 shares@ US$11.50Common StockSEC:0001104659-12-001583:1
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    10,642 USD0SEC
    3,400 shares@ US$3.13Common StockSEC:0001104659-11-064407:0
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    65,738 USD0SEC
    20,042 shares@ US$3.28Common StockSEC:0001104659-11-064407:1
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    231,373 USD0SEC
    23,442 shares@ US$9.87Common StockSEC:0001104659-11-064407:2
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    673,524 USD0SEC
    70,600 shares@ US$9.54Common StockSEC:0001104659-11-000851:0
  • ◇
    VP, Clinical DevelopmentExecutivesVivus Inc
    195,600 USD0SEC
    60,000 shares@ US$3.26Common StockSEC:0001104659-10-063416:0
  • ▼
    VP, Clinical DevelopmentExecutivesVivus Inc
    635,364 USD0SEC
    66,600 shares@ US$9.54Common StockSEC:0001104659-10-063416:1
  • ▲
    VP, Clinical ResearchExecutivesVivus Inc
    13,748 USD0SEC
    3,297 shares@ US$4.17Common StockSEC:0001255442-08-000023:0
    Canonical exit: 12 Aug 2008 (T+90)
  • ▲
    VP, Clinical ResearchExecutivesVivus Inc
    13,130 USD0SEC
    3,104 shares@ US$4.23Common StockSEC:0001255442-07-000045:0
    Canonical exit: 12 Feb 2008 (T+90)
  • ▲
    VP, Clinical ResearchExecutivesVivus Inc
    12,987 USD0SEC
    4,244 shares@ US$3.06Common StockSEC:0001255442-07-000022:0
    Canonical exit: 12 Aug 2007 (T+90)

25 of 27 declarations